Alterogen has experienced a significant stock price drop, leading to its loss of the top spot in the KOSDAQ market, but its fundamentals remain strong with impressive growth and profitability projections.
Alterogen, a biopharmaceutical research and development company, has recently faced a sharp decline in its stock price, which resulted in the loss of its position as the largest company by market capitalization on the KOSDAQ. Despite this setback, the company has shown impressive performance metrics, with projected revenues of 202.1 billion KRW and an operating profit of 11.48 billion KRW by 2025, marking increases of 117% and 275% from 2024. The operating profit margin stands at a robust 57%, suggesting strong profitability, yet the significant market capitalization of 20 trillion KRW appears exaggerated when compared to revenue and profit, as the price-to-earnings ratios are exceedingly high at 99x and 174x, respectively.
The decline in stock price has been attributed to a market correction given the previous overvaluation in relation to the company’s financial performance. However, it is posited that in the biotech industry, investor focus should be more on technological capabilities and future growth potential rather than immediate financial metrics. Alterogen has established several technology export contracts with ten global pharmaceutical and biotech companies, indicating its strong technological foundation, evidenced by a total contract value of 4.3 billion USD. Although a recent technology export deal with a U.S. firm yielded a disappointingly low contract value, which may have contributed to the stock’s decline, the overall technology and product pipeline remain promising for future growth.
To analyze or invest in pharmaceutical and biotech firms, understanding technology exports is crucial. Successful longevity in this industry is contingent upon developing effective new drugs and effectively marketing them to hospitals and pharmacies. Consequently, firms focus intensively on the development of groundbreaking drugs. Smaller companies in South Korea, however, can often capitalize on the market by developing improved versions of off-patent drugs without incurring significant development costs, although the domestic market size may limit extended growth for these smaller firms.
